Growth Hormone Research Society Workshop Summary: Consensus Guidelines for Recombinant Human Growth Hormone Therapy in Prader-Willi Syndrome
Top Cited Papers
Open Access
- 1 June 2013
- journal article
- review article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 98 (6), E1072-E1087
- https://doi.org/10.1210/jc.2012-3888
Abstract
Context: Recombinant human GH (rhGH) therapy in Prader-Willi syndrome (PWS) has been used by the medical community and advocated by parental support groups since its approval in the United States in 2000 and in Europe in 2001. Its use in PWS represents a unique therapeutic challenge that includes treating individuals with cognitive disability, varied therapeutic goals that are not focused exclusively on increased height, and concerns about potential life-threatening adverse events. Objective: The aim of the study was to formulate recommendations for the use of rhGH in children and adult patients with PWS. Evidence: We performed a systematic review of the clinical evidence in the pediatric population, including randomized controlled trials, comparative observational studies, and long-term studies (>3.5 y). Adult studies included randomized controlled trials of rhGH treatment for ≥ 6 months and uncontrolled trials. Safety data were obtained from case reports, clinical trials, and pharmaceutical registries. Methodology: Forty-three international experts and stakeholders followed clinical practice guideline development recommendations outlined by the AGREE Collaboration (www.agreetrust.org). Evidence was synthesized and graded using a comprehensive multicriteria methodology (EVIDEM) (http://bit.ly.PWGHIN). Conclusions: Following a multidisciplinary evaluation, preferably by experts, rhGH treatment should be considered for patients with genetically confirmed PWS in conjunction with dietary, environmental, and lifestyle interventions. Cognitive impairment should not be a barrier to treatment, and informed consent/assent should include benefit/risk information. Exclusion criteria should include severe obesity, uncontrolled diabetes mellitus, untreated severe obstructive sleep apnea, active cancer, or psychosis. Clinical outcome priorities should vary depending upon age and the presence of physical, mental, and social disability, and treatment should be continued for as long as demonstrated benefits outweigh the risks.Keywords
This publication has 131 references indexed in Scilit:
- Psychiatric illness in a cohort of adults with Prader-Willi syndromeResearch in Developmental Disabilities, 2011
- Bone Age Advancement in Prepubertal Children With Obesity and Premature Adrenarche: Possible Potentiating FactorsObesity, 2011
- Nutritional phases in Prader–Willi syndromeAmerican Journal of Medical Genetics Part A, 2011
- Psychiatric adverse effects of rimonobant in adults with Prader Willi syndromeEuropean Journal of Medical Genetics, 2011
- The Metabolic Phenotype of Prader-Willi Syndrome (PWS) in Childhood: Heightened Insulin Sensitivity Relative to Body Mass IndexJournal of Clinical Endocrinology & Metabolism, 2011
- Long-Term Growth Hormone Therapy Changes the Natural History of Body Composition and Motor Function in Children with Prader-Willi SyndromeJournal of Clinical Endocrinology & Metabolism, 2010
- Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decisionmaking framework to growth hormone for Turner syndrome patientsCost Effectiveness and Resource Allocation, 2010
- Evidence and Value: Impact on DEcisionMaking – the EVIDEM framework and potential applicationsBMC Health Services Research, 2008
- Synopsis of the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and childrenCMAJ : Canadian Medical Association Journal, 2007
- Sudden death in growth hormone–treated children with Prader-Willi syndromeThe Journal of Pediatrics, 2004